{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:06:29Z","timestamp":1761512789767},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,3,19]],"date-time":"2010-03-19T00:00:00Z","timestamp":1268956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold><jats:styled-content>Purpose:<\/jats:styled-content>\u2002<\/jats:bold> To evaluate the safety, tolerability, and efficacy of long\u2010term pregabalin as add\u2010on therapy for patients with poorly controlled partial seizures.<\/jats:p><jats:p><jats:bold><jats:styled-content>Methods:<\/jats:styled-content>\u2002<\/jats:bold> Analysis of data from six long\u2010term clinical trials involving 2,061 patients receiving open\u2010label pregabalin 75\u2013600\u2003mg\/day adjunctive therapy for partial onset epilepsy refractory to multiple antiepileptic drugs.<\/jats:p><jats:p><jats:bold><jats:styled-content>Results:<\/jats:styled-content>\u2002<\/jats:bold> Total pregabalin exposure was 3,877 person\u2010years. The mean duration of pregabalin treatment was 534\u2003days (range 0.3\u20138\u2003years) and 59% completed 1\u2003year. One\u2010third of patients discontinued for lack of efficacy. The most common dose was \u2265300\u2003mg\/day; over half took \u2265450\u2003mg\/day. There was a mean reduction in the 28\u2010day seizure rate of 25\u201340%, and more than 40% of all patients had a \u226550% reduction in seizures from baseline during the last 3\u2003months of treatment. Twelve percent of all patients had a 6\u2010month period continuously free of seizures. In the last year, 6% were seizure\u2010free for the entire year. Pregabalin was generally well\u2010tolerated and the safety profile favorable in patients treated for up to several years, with an adverse event (AE) profile similar to short\u2010term placebo\u2010controlled trials. Common AEs included CNS symptoms (dizziness, somnolence, headache, and asthenia), accidental injury, and weight gain. CNS AEs tended to be mild and transient. Rates of sudden unexpected death in epilepsy (SUDEP), mortality, cancer, and status epilepticus were within the expected range for this population.<\/jats:p><jats:p><jats:bold><jats:styled-content>Conclusions:<\/jats:styled-content>\u2002<\/jats:bold> Adjunctive pregabalin was effective, generally well tolerated, and safe in the long\u2010term treatment of partial seizures, and provided clinically meaningful seizure reduction and freedom without evidence of tolerance over 2\u2003years of follow\u2010up.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2010.02532.x","type":"journal-article","created":{"date-parts":[[2010,3,20]],"date-time":"2010-03-20T23:12:34Z","timestamp":1269126754000},"page":"968-978","source":"Crossref","is-referenced-by-count":18,"title":["Long\u2010term add\u2010on pregabalin treatment in patients with partial\u2010onset epilepsy: Pooled analysis of open\u2010label clinical trials"],"prefix":"10.1111","volume":"51","author":[{"given":"Basim M.","family":"Uthman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl W.","family":"Bazil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Beydoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schulze\u2010Bonhage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reina","family":"Benabou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birol","family":"Emir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Griesing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,6]]},"reference":[{"issue":"7","key":"e_1_2_7_2_1","first-page":"109","article-title":"Pregabalin in\u2010patient monotherapy trial: study results and impact of seizure frequency on efficacy evaluations","volume":"40","author":"Abou\u2010Khalil BW","year":"1999","journal-title":"Epilepsia"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.31203.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.43.s.6.12.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01128.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.455003.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000150932.48688.BE"},{"issue":"7","key":"e_1_2_7_8_1","first-page":"84","article-title":"Population pharmacokinetic (PK) analyses of commonly prescribed antiepileptic drugs (AEDs) coadministered with pregabalin (PGB) in adult patients with refractory partial seizures","volume":"42","author":"Bockbrader HN","year":"2001","journal-title":"Epilepsia"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.455004.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.8_suppl_5.S2"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.19204.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.1999.0348"},{"key":"e_1_2_7_14_1","volume-title":"Coding symbols for a thesaurus of adverse event reaction terms (COSTART)","author":"Department of Health and Human Services","year":"1996"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.10094"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.00341.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(01)00172-1"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000068024.20285.65"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.00263.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2007.02.006"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00049-3"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb01061.x"},{"key":"e_1_2_7_23_1","volume-title":"Cancer Trends Progress Report\u20142005 Update","author":"National Cancer Institute, NIH, DHHS","year":"2005"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2005.01327.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb06027.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(93)90070-N"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2005.05.004"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.00411.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200023010-00003"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2006.00705.x"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2010.02532.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2010.02532.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T21:42:52Z","timestamp":1698788572000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2010.02532.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1528-1167.2010.02532.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02532.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}